Long-term immunosuppressive therapy for inflammatory eye disease – the link between systemic treatment, cardiovascular risk and disease?

References

• Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690–1697.
   PubMed Web of Science ®Google Scholar
• Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70:929–934.
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2013;273:197–204.
   PubMed Web of Science ®Google Scholar
• Wiseman SJ, Ralston SH, Wardlaw JM. Cerebrovascular disease in rheumatic diseases: a systematic review and meta-analysis. Stroke. 2016;47:943–950.
   PubMed Web of Science ®Google Scholar
• Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs. 2004;64:2047–2073.
   PubMed Web of Science ®Google Scholar
• Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;2:807–818.
   PubMed Web of Science ®Google Scholar
• Veroux M, Corona D, Giuffrida G, et al. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression. Transplant Proc. 2008;40:1885–1887.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension. The Framingham study. Circulation. 1980;61:1179–1182.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med. 1979;90:85–91.
   PubMed Web of Science ®Google Scholar
• Van Halm VP, Peters MJ, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis. 2009;68:1395–1400.
   PubMed Web of Science ®Google Scholar
• Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin. 2005;45:1–13.
   PubMedGoogle Scholar
• Wakefield D, McCluskey P, Wildner G, et al. Inflammatory eye disease: pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: recommendations from an expert committee. Autoimmun Rev. 2017;16:213–222.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.
   PubMed Web of Science ®Google Scholar
• Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol. 2000;16:505–511.
   PubMed Web of Science ®Google Scholar
• Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens Res. 1996;19:1–8.
   PubMedGoogle Scholar
• Magiakou MA, Smyrnaki P, Chrousos GP. Hypertension in Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab. 2006;20:467–482.
   PubMed Web of Science ®Google Scholar
• Ferrau F, Korbonits M. Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol. 2015;173:M133–M157.
   PubMed Web of Science ®Google Scholar
• Panoulas VF, Douglas KMJ, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology. 2008;47:72–75.
   PubMed Web of Science ®Google Scholar
• Davis JM 3rd, Maradit-Kremers H, Gabriel SE. Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? J Rheumatol. 2005;32:1856–1862.
   PubMed Web of Science ®Google Scholar
• Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res. 2012;64:1282–1291.
   Web of Science ®Google Scholar
• Yuen KCJ, Chong LE, Riddle MC. Influence of glucocorticoids and growth hormone on insulin sensitivity in humans. Diabetic Med. 2013;30:651–663.
   PubMed Web of Science ®Google Scholar
• Udoetuk JD, Dai Y, Ying GS, et al. Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. Ophthalmology. 2012;119:1569–1574.
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764–770.
   PubMed Web of Science ®Google Scholar
• Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1-15;quiz 6-8.
   PubMed Web of Science ®Google Scholar
• Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108:1362–1370.
   PubMed Web of Science ®Google Scholar
• Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10:R30.
   PubMed Web of Science ®Google Scholar
• Morgan SL, Baggott JE, Lee JY, et al. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol. 1998;25:441–446.
   PubMed Web of Science ®Google Scholar
• Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology. 2010;49:295–307.
   PubMed Web of Science ®Google Scholar
• Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum. 2009;38:372–381.
   PubMed Web of Science ®Google Scholar
• Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment–a prospective, controlled study. Arthritis Res Ther. 2006;8:R82.
   PubMed Web of Science ®Google Scholar
• Papadakis JA, Sidiropoulos PI, Karvounaris SA, et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clin Exp Rheumatol. 2009;27:292–298.
   PubMed Web of Science ®Google Scholar
• Navarro-Millan I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 2013;65:1430–1438.
   PubMed Web of Science ®Google Scholar
• Pirkmajer S, Kulkarni SS, Tom RZ, et al. Methotrexate promotes glucose uptake and lipid oxidation in skeletal muscle via AMPK activation. Diabetes. 2015;64:360–369.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. Jama. 2011;305:2525–2531.
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014;8:67–81.
   PubMedGoogle Scholar
• David KM, Morris JA, Steffen BJ, et al. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant. 2005;19:279–285.
   PubMed Web of Science ®Google Scholar
• Muller DN, Dechend R, Mervaala EM, et al. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 2000;35:193–201.
   PubMed Web of Science ®Google Scholar
• Quiroz Y, Pons H, Gordon KL, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol. 2001;281:F38–F47.
   PubMed Web of Science ®Google Scholar
• Herrera J, Ferrebuz A, MacGregor EG, et al. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol. 2006;17:S218–S225.
   PubMed Web of Science ®Google Scholar
• Moreno JM, Rubio E, Gomez A, et al. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. Transplant Proc. 2003;35:1874–1876.
   PubMed Web of Science ®Google Scholar
• Akman B, Uyar M, Afsar B, et al. Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids. Transplant Proc. 2007;39:135–137.
   PubMed Web of Science ®Google Scholar
• Thapa SD, Hadid H, Schairer J, et al. Effect of inflammatory bowel disease-related characteristics and treatment interventions on cardiovascular disease incidence. Am J Med Sci. 2015;350:175–180.
   PubMed Web of Science ®Google Scholar
• Wakefield D, McCluskey P. Cyclosporine: a therapy in inflammatory eye disease. J Ocul Pharmacol. 1991;7:221–226.
   PubMedGoogle Scholar
• Remuzzi G, Perico N. Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int Suppl. 1995;52:S70–S74.
   PubMedGoogle Scholar
• Sander M, Lyson T, Thomas GD, et al. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens. 1996;9:121S–38S.
   PubMed Web of Science ®Google Scholar
• Taler SJ, Textor SC, Canzanello VJ, et al. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf. 1999;20:437–449.
   PubMed Web of Science ®Google Scholar
• Bouhaddi M, Delbosc B, Fortrat JO, et al. Six-month cardiovascular changes in cyclosporine-treated recipients of corneal grafts: serial baroreflex responses. Transpl Int. 2004;17:325–333.
   PubMed Web of Science ®Google Scholar
• Kim WU, Seo YI, Park SH, et al. Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis. Ann Rheum Dis. 2001;60:514–517.
   PubMed Web of Science ®Google Scholar
• Tugwell P, Bombardier C, Gent M, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet. 1990;335:1051–1055.
   PubMed Web of Science ®Google Scholar
• Markham T, Watson A, Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol. 2002;27:111–114.
   PubMed Web of Science ®Google Scholar
• Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients. Am J Clin Dermatol. 2001;2:41–47.
   PubMedGoogle Scholar
• Deray G, Le Hoang P, Cacoub P, et al. Renal function and blood pressure in patients treated with cyclosporin A for uveitis. Eur J Clin Pharmacol. 1988;34:601–604.
   PubMed Web of Science ®Google Scholar
• Redmon JB, Olson LK, Armstrong MB, et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest. 1996;98:2786–2793.
   PubMed Web of Science ®Google Scholar
• Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation. 1999;68:396–402.
   PubMed Web of Science ®Google Scholar
• Penninga L, Penninga EI, Moller CH, et al. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev. 2013;5:CD008817.
   Google Scholar
• Rathi M, Rajkumar V, Rao N, et al. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study. Transplant Proc. 2015;47:1158–1161.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506–1514.
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant. 2006;25:434–439.
   PubMed Web of Science ®Google Scholar
• Hogan AC, McAvoy CE, Dick AD, et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114:1000–1006.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785–96 e3.
   PubMed Web of Science ®Google Scholar
• Kim KI, Lee JH, Chang HJ, et al. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J. 2008;72:293–298.
   PubMed Web of Science ®Google Scholar
• Zinman B, Hanley AJ, Harris SB, et al. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab. 1999;84:272–278.
   PubMed Web of Science ®Google Scholar
• Elmarakby AA, Quigley JE, Pollock DM, et al. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension. 2006;47:557–562.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Takeuchi T, Kotani T, et al. Infliximab, a TNF-alpha inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients. J Hum Hypertens. 2014;28:165–169.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352–356.
   PubMed Web of Science ®Google Scholar
• Feingold KR, Soued M, Staprans I, et al. Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNF-induced hyperlipidemia. J Clin Invest. 1989;83:1116–1121.
   PubMed Web of Science ®Google Scholar
• Popa C, van Tits LJ, Barrera P, et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis. 2009;68:868–872.
   PubMed Web of Science ®Google Scholar
• O’Neill F, Charakida M, Topham E, et al. Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis. Heart. 2016:1–8.
   PubMed Web of Science ®Google Scholar
• Jamnitski A, Levels JH, van den Oever IA, et al. High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study. J Rheumatol. 2013;40:825–830.
   PubMed Web of Science ®Google Scholar
• Daien CI, Duny Y, Barnetche T, et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis. 2012;71:862–868.
   PubMed Web of Science ®Google Scholar
• Pollono EN, Lopez-Olivo MA, Lopez JA, et al. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol. 2010;29:947–955.
   PubMed Web of Science ®Google Scholar
• Burska AN, Sakthiswary R, Sattar N. Effects of tumour necrosis factor antagonists on insulin sensitivity/resistance in rheumatoid arthritis: a systematic review and meta-analysis. Plos One. 2015;10:e0128889.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Rowan CG, Bebchuk JD, et al. No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients. J Drugs Dermatol. 2015;14:159–166.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005;64:765–766.
   PubMed Web of Science ®Google Scholar
• Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012;14:R141.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:83–86.
   PubMed Web of Science ®Google Scholar
• Pina T, Corrales A, Lopez-Mejias R, et al. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: a 6-month prospective study. J Dermatol. 2016;43:1267–1272.
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, Santos-Gomez M, Calvo I, et al. Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol. 2017;69:668–675.
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88–96.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761–1769.
   PubMed Web of Science ®Google Scholar
• Kim SC, Solomon DH, Rogers JR, et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheumatol. 2017;69:1154–1164.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905–2912.
   PubMed Web of Science ®Google Scholar
• Barnabe C, Martin BJ, Ghali WA. ystematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63:522–529.
   PubMed Web of Science ®Google Scholar
• Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016:1–12.
   Web of Science ®Google Scholar
• Yates WB, Vajdic CM, Na R, et al. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study. Ophthalmology. 2015;122:265–273.
   PubMed Web of Science ®Google Scholar